Briefing
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for BCG-unresponsive NMIBC.
CR at 6 months: 13% of UroAmp+ vs 71% of UroAmp- at baseline (P<0.001).
- n: UroAmp at baseline n=89 and 3 months n=77
- Assay: UroAmp